Shai Levi, Yotam Bronstein, Neta Goldschmidt, Fortunato Morabito, Tomer Ziv‐Baran, Giovanni Del Poeta, Osnat Bairey, Maria Ilaria Del Principe, Riva Fineman, Francesca Romana Mauro, Odit Gutwein, Gianluigi Reda, Rosa Ruchlemer, Paolo Sportoletti, Luca Laurenti, Lev Shvidel, Marta Coscia, Tamar Tadmor, Marzia Varettoni, Ariel Aviv, Roberta Murru, Andrei Braester, Annalisa Chiarenza, Andrea Visentin, Daniela Pietrasanta, Giacomo Loseto, Antonella Zucchetto, Riccardo Bomben, Jacopo Olivieri, Antonio Neri, Davide Rossi, Gianluca Gaïdano, Livio Trentin, Robin Foà, Antonio Cuneo, Chava Perry, Valter Gattei, Massimo Gentile, Yair Herishanu,
In recent years, there has been a dramatic change in the treatment landscape of chronic lymphocytic leukemia (CLL). The chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) has been shown to prolong progression-free survival (PFS) and overall survival (OS) compared to FC alone in previously untreated CLL patients.1 Consequently, until recently FCR has become the treatment of choice in young fit patients with CLL. Ibrutinib, a first-in-class covalent inhibitor of Bruton's ...
Tópico(s): Lymphoma Diagnosis and Treatment
2022 - Wiley | American Journal of Hematology
Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Anna Grazia Recchia, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Enrica Antonia Martino, Ernesto Vigna, Giovanni Tripepi, Graziella D’Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Ozren Jakšić, Jacopo Olivieri, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaïdano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile,
... Murru, Annalisa Chiarenza, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, V.F., Hamdi Al-Janazreh, Jacopo Olivieri, Ernesto Vigna, Angela Rago, Ilaria Angeletti, Andrea ...
Tópico(s): Immunodeficiency and Autoimmune Disorders
2021 - Wiley | American Journal of Hematology
Antonio Cuneo, Gian Matteo Rigolin, Marta Coscia, Giulia Quaresmini, Lydia Scarfò, Francesca Romana Mauro, Marina Motta, Francesca Maria Quaglia, Livio Trentin, Andrea Ferrario, Luca Laurenti, Gianluigi Reda, Angela Ferrari, Daniela Pietrasanta, Paolo Sportoletti, Francesca Re, Lorenzo De Paoli, Myriam Foglietta, Annamaria Giordano, Monia Marchetti, Lucia Farina, Giovanni Del Poeta, Marzia Varettoni, Federico Chiurazzi, Roberto Marasca, Lara Malerba, Adalberto Ibatici, Maria Chiara Tisi, Vittorio Stefoni, Monica Leone, Claudia Baratè, Jacopo Olivieri, Roberta Murru, Massimo Gentile, Alessandro Sanna, Alessandro Gozzetti, Valter Gattei, Daniela Gottardi, Enrico Derenzini, Luciano Levato, Lorella Orsucci, Giuseppa Penna, Annalisa Chiarenza, Robin Foà,
Twelve months after the outbreak of COVID-19, the Campus CLL network that involves hematology centers throughout Italy completed a survey (Tables 1 and 2) aimed at collecting information on the treatment of chronic lymphocytic leukemia (CLL) patients in the different phases of the pandemic - that is, phase 1 (February–May 2020), phase 2 (June–September 2020) and phase 3 (October 2020–January 2021), as well as on the vaccination program. During the year of the pandemic, 494 cases of COVID-19 infection were ...
Tópico(s): Acute Lymphoblastic Leukemia research
2021 - Wiley | Hematological Oncology
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Ernesto Vigna, Enrica Antonia Martino, Ramona Cassin, Graziella D’Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Jacopo Olivieri, Giovanna Cutrona, Davide Rossi, Antonio Cuneo, Francesco Di Raimondo, Gianluca Gaïdano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile,
Ibrutinib (IB) has been initially approved for naïve patients' treatment with chronic lymphocytic leukemia (CLL) based on its superiority over chlorambucil.1 Two subsequent large phase 3 randomized trials demonstrated a longer progression-free survival (PFS) in IB treated cases compared to those receiving rituximab (R) combined with fludarabine (F) and cyclophosphamide (C, FCR)2 or with bendamustine (BR).3 Explorative analyses, demonstrating the superiority of IB over chemotherapy1 or chemoimmunotherapy2, ...
Tópico(s): Immunodeficiency and Autoimmune Disorders
2021 - Wiley | American Journal of Hematology